This article is more than 5 years old. Information may no longer be current.
Clearside completes enrollment in phase 2 trial of CLS-TA for macular edema in noninfectious uveitis
Click Here to Manage Email Alerts
Clearside Biomedical completed enrollment in a phase 2 clinical trial of CLS-TA using suprachoroidal space drug administration to treat macular edema associated with noninfectious uveitis, according to a press release.
The phase 2 Dogwood trial to evaluate CLS-TA (triamcinolone acetonide) has a primary efficacy endpoint of mean change from baseline in retinal thickness at 2 months after treatment and secondary efficacy endpoints of visual acuity improvements at months 1 and 2 after treatment, the release said.
Over the 2-month follow-up, safety, including the incidence of adverse events, serious adverse events and increases in IOP, will be evaluated.
Top-line data from the phase 2 trial should be reported later this year, and a pivotal phase 3 clinical trial is expected to begin patient enrollment by December, according to the release.